This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Feb. 21, 2013 /PRNewswire/ --
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) today announced that it has entered into an exclusive agreement with
Sandor Medicaids Pvt. Ltd., an
India-based pharmaceutical company, for the commercialization of Caldolor
ibuprofen) Injection in
Under the terms of the agreement, Sandor Medicaids Pvt. Ltd.
is responsible for seeking regulatory approval for Caldolor and, following approval, would handle ongoing distribution and sales in the territory.
Cumberland maintains responsibility for product formulation, development and manufacturing, and will provide finished product for sale. In exchange for the license to the product,
Cumberland will receive upfront and milestone payments, a transfer price and royalties on future sales of Caldolor.
"We believe Caldolor can fill an unmet need in the hospital market in
India, and look forward to communicating its benefits to the medical community here," said Rajeev Sindhi, Managing Director for Sandor Medicaids Pvt. Ltd. "
Cumberland's strong clinical data and profile for use of the product should help facilitate regulatory approval and encourage widespread hospital use in our country."
Used primarily in hospitalized patients who are unable to receive oral therapies, Caldolor is expected to be the first and only injectable ibuprofen product available in
India for the treatment of pain and fever, featuring analgesic, antipyretic and anti-inflammatory properties.
"We are very pleased to expand our network of international partners for Caldolor with this new agreement," said
A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Sandor has an established infrastructure to handle commercialization of hospital pharmaceutical products, and we look forward to working with them to make Caldolor available to a larger population of patients."
About Caldolor ®
Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit
Sandor MedicaidsSandor Medicaids Pvt. Ltd is a medical and drug distribution firm. Since its establishment in 1995 at
Hyderabad, the company focuses on providing high technology biomedical and biotechnology products to the Indian patient. Sandor is recognized as a pioneer in bringing in
"Point of Care" concept in the Indian Health Care Industry. Sandor's marketing and distribution team is comprised of experienced professionals from the Health Care Industry across the country. They ensure the products of our partners reach the customers at the Right Time, to the Right Place, in the Right form and for the Right Price. A sub-network of 15 distribution centers ably supports Sandor's existing efficient and effective
COLD CHAIN DISTRIBUTION network in the 16 major cities of the country. The entire network is centrally monitored from the Sandor Head Office at Hyderabad Sandor offers a complete range of Logistics & Distribution management, Regulatory services to manufactures in specialty drugs, medical devices and hospital supplies industries.
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote
acetylcysteine) Injection for the treatment of acetaminophen poisoning; Caldolor
ibuprofen) Injection, the first injectable treatment for pain and fever available in the
United States; and Kristalose
lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products which improve quality of care for patients. For more information, please visit the company website at
Important Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that reflect Cumberland's current views with respect to future events, based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of operations are subject to influences outside of the Company's control. Risk factors that could materially affect results of operations include, among other things, market conditions, intense competition from existing and new products, an inability of manufacturers to produce Acetadote on a timely basis or a failure of manufacturers to comply with stringent regulations applicable to drug manufacturers, maintaining and building an effective sales and marketing infrastructure, government regulation, the possibility that patent rights may provide only limited protection from competition, and other factors related to the Company including those under the headings "Risk factors" and "Management's discussion and analysis of financial condition and results of operations" in Cumberland's Form 10-K filed with the SEC on March 7, 2012. There can be no assurance that the results or developments anticipated by Cumberland will be realized or, if realized, that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. Cumberland undertakes no obligation to release publicly any revisions to these statements to reflect events or circumstances after the date hereof.